Prostate Carcinoma Determination via Alpha-2,3-Glycan PSA Ratio
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining prostate carcinoma (Pca) face challenges in accurately diagnosing Pca, especially in the gray zone of total PSA values, and struggle to differentiate between benign and malignant Pca, with limited accuracy and invasiveness.
Innovation Solution
Measuring the ratio of free PSA with an α(2,3)-linked glycan to total free PSA in a biological sample, where a ratio higher than 40% indicates Pca development and higher than 47% suggests malignancy, using specific antibodies and lectins for precise glycan detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If needle biopsy is performed to obtain definite diagnosis in gray zone, then diagnostic accuracy is improved, but risk of infectious diseases increases
Solution Approach 1:
The patent replaces the mechanical needle biopsy procedure with a biochemical detection system using lectin affinity chromatography to separate and quantify free PSA based on glycan structure. This substitution eliminates the need for invasive physical sampling while providing molecular-level diagnostic information through measurement of α(2,3)-linked sialic acid-containing free PSA ratios.
Solution Approach 2:
The patent introduces lectin (specifically Maackia amurensis lectin or Sambucus nigra lectin) as an intermediary substance that selectively binds to free PSA molecules containing α(2,3)-linked sialic acid glycans. This intermediary enables indirect detection of prostate carcinoma through affinity chromatography separation, allowing diagnostic information to be obtained without direct tissue sampling.
2Ease of operation
If total PSA value is used for Pca determination, then ease of measurement is improved, but diagnostic accuracy in gray zone deteriorates
Solution Approach 1:
The patent applies local quality by focusing detection on a specific subset of free PSA molecules that contain α(2,3)-linked sialic acid glycans, rather than measuring all PSA uniformly. This selective detection of molecules with specific glycan structures provides localized molecular information that distinguishes carcinoma from benign conditions, thereby improving diagnostic precision while maintaining the simplicity of serum-based measurement.
Solution Approach 2:
The patent changes the measurement parameter from total PSA concentration to the ratio of free PSA with α(2,3)-linked sialic acid glycans to total free PSA. This parameter transformation converts a simple concentration measurement into a structurally-specific ratio that enhances diagnostic discrimination in the gray zone while building upon the existing total PSA measurement framework.
3Measurement precision
If conventional PSA indices (PSA density, PSA gradient, free PSA/total PSA ratio) are used, then diagnostic accuracy is partially improved, but ability to differentiate benign and malignant Pca deteriorates
Solution Approach 1:
The patent adds another dimension to PSA analysis by incorporating glycan structural information (α(2,3)-linked sialic acid presence) as a new diagnostic parameter. This dimensional addition moves beyond conventional one-dimensional concentration ratios to a two-dimensional assessment combining PSA quantity with glycan structure, thereby preserving and enhancing the ability to differentiate between benign and malignant prostate conditions.
Solution Approach 2:
The patent employs a composite detection approach combining lectin affinity chromatography with immunoassay techniques. The lectin-PSA-glycan complex formed through specific glycan-lectin interactions creates a composite system that separates free PSA based on glycan structure, enabling simultaneous assessment of multiple molecular characteristics that improve differentiation between benign and malignant prostate carcinoma.
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
An object of the present invention is to provide a novel Pca determination method and a Pca malignancy determination method. The present invention is an invention relating to a "prostate carcinoma determination method, including determining the ratio of the amount of free prostate specific antigen, which has a glycan in which the terminal sialic acid residue of the glycan is α(2,3)-linked to a second galactose residue from the terminal of the glycan, to the amount of free PSA in a biological sample, and then determining that prostate carcinoma is developed or the probability of developing prostate carcinoma is high in the case where the ratio is 40% or higher."